A Treatment Option in Myelofibrosis

Dates/Times: Tuesday, April 28, 2020 at 5 PM EDT and 8 PM EDT and Thursday, April 30, 2020 at 5 PM EDT and 8 PM EDT

This OncLive webinar will uncover the latest treatments in myelofibrosis with Bart Scott, MD, a board certified oncologist at SCCA, an assistant member of the Fred Hutchinson Cancer Research Center and a UW assistant professor of Oncology.

Click here to register today!

Course Objectives:

1. Clinical data supporting a treatment option for patients with intermediate-2 or high risk myelofibrosis

1. NCCN Clinical Practice Guidelines surrounding use of the new treatment option in myelofibrosis
2. Safety, adverse event management, and dose modifications
3. Steps for starting your patients on this treatment option

Speakers:

Assistant Professor, Oncology at University of Washington School of Medicine

Dr. Scott’s area of expertise is myelodysplastic syndrome and myeloproliferative disorders. He believes that patients should be the principal decision makers regarding their care. He thinks it is very important to respect the desire and wishes of each individual patient.

Dr. Scott earned his M.D. at the UW. His interests include clinical trial development in patients with myeloid malignancies.